Understand the source comparison
Peptides for ADHD vs Prescription Stimulants: Comparison
The table below contrasts peptides for ADHD with FDA-approved stimulant medications across mechanism, evidence base, regulatory status, and clinical utility. Prescription Stimulants (methylphenidate, amphetamine) Dopamine and norepinephrine reuptake inhibition
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below contrasts peptides for ADHD with FDA-approved stimulant medications across mechanism, evidence base, regulatory status, and clinical utility.
- Prescription Stimulants (methylphenidate, amphetamine)
- Dopamine and norepinephrine reuptake inhibition; direct agonism at dopamine receptors
- Hundreds of RCTs, meta-analyses showing 70–80% response rate in symptom reduction
- FDA-approved for ADHD treatment (Schedule II controlled substances)
- First-line pharmacotherapy for ADHD across age groups
- Proven efficacy, well-characterised safety profile, regulatory oversight
- Cerebrolysin (peptide mixture)
- BDNF and NGF upregulation; neuroprotective and neuroplasticity-promoting effects
- One small pediatric ADHD study (n=60), no replication; primary evidence base is stroke/TBI recovery
- Not FDA-approved for any indication in the US; used clinically in Europe/Asia for neurodegenerative conditions
- Research or off-label use in neuroplasticity contexts
- Biological plausibility exists, but human ADHD evidence is insufficient for therapeutic recommendation
- Dihexa, P21 (synthetic peptides)
- HGF receptor agonism (dihexa), CNTF pathway modulation (P21); synaptogenesis and dendritic spine formation
- Rodent cognition studies only; no human trials for ADHD or any cognitive indication
- Not FDA-approved; available as research chemicals only
- Laboratory research on neuroplasticity mechanisms
- Promising preclinical data, but absence of human dosing studies and safety profiles precludes clinical use
- Semax, Selank (synthetic peptides)
- ACTH analogue (semax) modulating dopamine metabolism; tuftsin analogue (selank) with anxiolytic and cholinergic effects
- Small studies in healthy adults showing attention improvements; no ADHD-specific trials
- Not FDA-approved; used clinically in Russia, available as research peptides elsewhere
- Research use or off-label cognitive enhancement
- Mechanistic rationale exists, but evidence is limited to non-ADHD populations and lacks long-term safety data